Quick Answer
You're holding a CRO proposal that quotes a three-month tox-supply figure, or a vendor deck that promises IND readiness in six months, and you need to decide w…
What Lonza’s three-month tox supply and six-month IND claim actually covers
Wholesale Peptide Wholesale Enkephalin The claim is narrower than the headline. The accelerated biologics timeline rests on a specific material choice and a specific starting point, and both are footnoted on the pages that carry the numbers.
The bispecific programme page states “3 months to tox material supply” and “DNA to IND in as little as 6 zänä,” with the six-month footnote reading “Based on the use of pool material. From DNA transfection to delivery of IND-enabling CMC modules. Typical timelines. Subject to agreement with regulatory authorities” (the bispecific programme page). The same page offers an eight-month pathway footnoted “Based on the use of clonal material,” so the faster number depends on earlier-stage pool material rather than a clonal line (the clonal-material alternative).
The mAb programme carries the same structure at shorter intervals: “2 months to tox drug substance,” “3 months to tox drug product,” and DNA-to-IND in as little as 6 months on pool material, with an 8-month alternative on clonal material (Lonza’s mAb programme). The overview page adds an eligibility qualifier, describing toxicology drug substance “available as early as two months for eligible programs” (the DNA-to-IND programme overview).
Lonza’s own account of how the acceleration works is parallel execution rather than calendar compression: early analytical development, process development “built for robustness and scalability,” and regulatory readiness designed in from the outset (Lonza’s own account of how the acceleration works). Lonza’s six-month explainer frames the choice between six and eight months as a function of the molecule and development goal (Lonza’s six-month explainer).
The qualifier moves the number by 33%. A buyer who quotes six months without the pool-material footnote is quoting a different program than the one described.
Why a biologics platform timeline cannot be copied onto a peptide program
The same review reports production-scale SPPS reactors from hundreds of litres up to a 6000 L system, with peptides around 70 residues feasible in principle, and notes that inefficient coupling, low yield and excessive impurity formation are sometimes tied to secondary structure of the protected peptide on the resin. It also puts the practical length limit of SPPS at approximately 100 aminoácidos, because iterative synthesis “potentially generates a large number of impurities (e.g., deletion and truncation), with a chemical structure close to that of” the target (the practical length limit of SPPS).
Some sequences fail for structural reasons rather than length. The peptide literature’s definition of a difficult sequence covers peptides prone to intra- and interchain secondary structures, with hindered Fmoc removal and acylation and truncated or gapped byproducts that are difficult to separate from the target; aggregation-prone motifs include runs of β-methyl residues, alternating hydrophobic and bulky residues, and high glycine content (the peptide literature’s definition of a difficult sequence).
Purity data alone will not reveal all of it. In difficult-sequence syntheses, byproducts lacking internal residues, truncated peptides and Fmoc-retaining peptides were detectable only by ESI-MS/MS and MALDI-TOF, and several sequences yielded only trace target under a standard schedule (MS/MS detection of sequence-related byproducts).
The arithmetic is the argument. At 99.0% per-step success, a 40-residue chain leaves roughly two-thirds of the material full-length before purification; at 99.8%, roughly nine-tenths at 50 residues. A platform calendar cannot predict where a given sequence lands on that curve, which is why peptide synthesis scale decisions rest on measured coupling performance.
What sequence confirmation must prove before downstream data is trusted
Sequence confirmation is the gate that validates every later number. If identity is not established by more than one method, a purity figure describes an unknown substance.
The EMA’s synthetic-peptide guideline requires that “the structure of the peptide should be confirmed by analytical data,” including primary and, ho relevante, estructura ya mäs xi ngu, and recommends at least two orthogonal methods for identification at release, with mass, pa retención ir nge hmä, LC-MS, g, amino acid analysis or NMR all considered appropriate (the EMA’s synthetic-peptide guideline). The applicant must show the chosen combination unambiguously confirms the sequence.
ICH Q6B’s structure-confirmation logic sets the same expectation for sequence determination “to the extent possible,” listing amino acid composition, terminal sequence analysis, peptide mapping by HPLC and mass spectrometry, with validated peptide mapping “frequently used to confirm desired product structure for lot release purposes” (ICH Q6B’s structure-confirmation logic). Q6B also notes that synthetic peptides fall outside its scope, so the EMA document is the more specific authority for a chemically synthesized molecule.
Neither document supplies a numeric identity threshold, because ICH Q6B’s definition of a specification makes acceptance criteria “proposed and justified by the manufacturer and approved by regulatory authorities,” with purity acknowledged as method-dependent (definición ar ICH Q6B 'nar especificación).
Purity, identidad, content and assay answer four different questions. 'nar único porcentaje HPLC ge 'nar ndo'yo pureza. identidad t'ot'e confirmación ortogonal, contenido wa péptido neto péptido 'ño̲ho̲ requiere 'nar nt'ot'ise̲ ár njäts'i, ne adecuación ensayo bi jagu̲ju̲ 'nar estándar referencia. 'nar propuesta da ofrece 'nar 'bede ya certificado komongu ar prueba ya goho ya xi respondido 'nar nt'a̲ni.
petición ar evidencia ar concreta: ar versión secuencia jar ntsa̲, Ar par ortogonal utilizado ja ar lanzamiento, ne ya datos jar za̲ ár nthe̲ lote mostrando ga̲ yoho ya nt'ot'e nkohien.
What a defensible impurity profile contains at toxicology stage
Perfilado impureza peptídica corre jar umbrales da 'na'ño ya defectos t'olo molécula, and the difference ar suficientemente dätä pa mpa̲ti 'nar especificación.
Guía ar EMA sintético-péptido, ja ya ndu t'edi ndezu̲ ar Hunyo 2026, states that synthetic peptides are fully or partially excluded from ICH Q3A/B and that, per the Ph. Eur. general monograph “Substances for Pharmaceutical Use” (2034), peptide-related impurities should be reported above 0.1%, e 0.5% u 1.0% (the EMA’s synthetic-peptide guideline, ja ya ndu t'edi ndezu̲ ar Hunyo 2026). Where co-eluting impurities appear as one peak, the 1.0% e.
ICH Q3A(R2) sets the small-molecule defaults at 0.05% reporting, 0.10% identification and 0.15% qualification for a maximum daily dose up to 2 g/day, and its preamble lists peptide products among those not covered (ICH Q3A(R2)). Applying those numbers to a peptide is a scope error in the buyer’s favor, since they are tighter than the peptide thresholds.
The EMA guideline’s impurity taxonomy separates peptide-related impurities, which are structural elements of the sequence, from non-peptide impurities such as process reagents, residual solvents and elemental impurities. Peptide-related sources include starting-material defects (incorrect enantiomers and diastereomers, wrong amino acids, β-Ala residues, dipeptides) ne formación ar proceso (estereoisómeros epimerización, deletion sequences, truncamientos ar tapas) (ar taxonomía ar impurezas ar guía EMA).
'nar perfil ar ho̲ntho ngut'ä za̲ komongu ár nt'ot'e jár xu̲tha. ICH Q2(R2)características ar validación ’ s requieren 'nar pureza HPLC cuantitativa wa nt'ot'e impurezas pa abordar especificidad ne selectividad, incluyendo picos ko impurezas conocidas wa comparación ortogonal ne degradación forzada ho mahyoni, 'nar modelo calibración ko tso̲kwa menu ku̲t'a puntos mäs ntsoni ya cuantificación ne ya detección, accuracy, repetibilidad, precisión intermedia ne robustez, ne ar guía establece ningún criterio nxo̲ge jar nthä numérica (ICH Q2(R2)características ar validación s).
picos Co-eluing ocultan ar impureza nä'ä mäs t'ot'e ga. N, u 1.0% '. b.
FDA retiró ár Mäyo 2021 u 2026. � � borradores wa guía final ne ár hne; y 0.10%/0.5% o.
What evidence shows a peptide process is scalable, not just reproducible at one scale
h, o. ar distinción importa ngetho 'nar proceso funciona jar 0.1 i 6000 m.
ICH Q11’s position on scale effects is that a small-scale model “should account for scale effects and be representative of the proposed commercial process,” that scaling factors should be included for steps intended to span multiple operational scales when the step is scale dependent, and that small-scale data can reduce reliance on commercial-scale validation batches only once the model is shown scalable (ICH Q11’s position on scale effects).
Two published campaigns show what real production-scale peptide data look like. A published kilogram-scale tirzepatide campaign, a 39-residue peptide made by hybrid SPPS/LPPS with continuous manufacturing, reported approximately 81% overall activity yield with 8.71 kg isolated and crude purity around 90% by HPLC (a published kilogram-scale tirzepatide campaign). A matched small- versus production-scale comparison of liraglutide at 0.1 mmol and 25 mmol in a 3 L vessel gave 77–78% crude purity at production scale, matching wash-based results at research and production scale, with model crude purities around 75–84% (a matched small- versus production-scale comparison).
Per-step stereochemical fidelity does not by itself establish total epimer content in the isolated peptide. Measure relevant stereoisomeric impurities and distinguish analytical thresholds from product-specific acceptance criteria. Peptide Research
Request the scale-effect study, not the scale-up promise. The document to ask for is a comparison of at least two operational scales of the same process, with scaling factors stated for each scale-dependent step and impurity profiles compared side by side. 'Nar registro lote escala ho̲ntho hindi responde ar nt'a̲ni plantea ICH Q11.
Ni 'na jar fuente publicada cuantifica 'nar pérdida pureza típica ar mg da kg pa péptidos, nja'bu da japi 'na propuesta da ofrece 'na komongu hinda apoyo asta da muestran ya datos subyacentes.
Honja aplicamos 'me̲hna jar cambios MOL, editor nuna ar guía. ma 'be̲fi síntesis péptidos abarca cantidades miligramo ma kilogramo, nä'ä ge ar gama 'nar estudio escala-ntsoni pe̲ts'i da puente. nä'ä nä'ä hingi bí xta ge 'nar paquete ntsoni escala validado wa suministro clínico ar GMP; Tobe gi pe̲ts'i da 'ya̲ni ya datos ya 'nar escala ne juzgar gí xkagentho, ko 'na proveedor, nuestro incluido.
Which release tests and records are non-negotiable, and what a CoA must carry
plazos liberación dependen ya pruebas requeridas ne ya nt'ot'e validados. pruebas ar esterilidad compendial comúnmente gi japu̲'be̲fi 'nar incubación mínima 14 pa nu'bu̲ da aplicable, but not every peptide lot requires sterility testing, and justified alternative methods may have different timelines.
The records layer is where proposals most often thin out. The audit-trail requirement in 21 CFR 11.10(a) calls for “secure, �, time-stamped audit trails” that record operator entries and actions creating, modifying or deleting electronic records, with changes not obscuring previously recorded information and the trail retained at least as long as the subject records and available for agency review (the audit-trail requirement in 21 CFR 11.10(a)). MHRA’s ALCOA expectations define data as attributable, legible, contemporáneo, original and accurate, with complete, consistente, enduring and available added, and require that audit trails identified by risk assessment be switched on, that users cannot amend or disable them, and that an administrator override itself be recorded (MHRA’s ALCOA expectations). Peptide Factory Supplier
The IND CMC requirement in 21 CFR 312.23(a)(7) sets what the package must ultimately support: sufficient information “to assure the proper identification, quality, pureza, and strength of the investigational drug,” with emphasis in an initial Phase 1 submission on identification and control of raw materials and the new drug substance, final specifications not expected until the end of investigation, and information amendments required as scale changes from pilot to larger scale (the IND CMC requirement in 21 CFR 312.23(a)(7)).
A connected data package, not a certificate. The CoA should carry the sequence version tested, any modification site, the counterion form, the method identifier behind each result, and the lot number, and it should be traceable to the chromatograms and mass spectra that produced it. A summary certificate without the underlying records cannot be reconstructed, and MHRA’s guidance states that paper copies of dynamic electronic data cannot be considered raw data.
How peptide CRO selection turns a proposal into per-gate evidence requests
Peptide CRO selection reduces to one test: for each gate, does the proposal carry evidence you can inspect, or only a number you can quote? The four gates give you a fixed set of questions that applies to any supplier.
|
Gate |
Evidencia pa petición |
Standard it answers to |
|---|---|---|
|
Confirmación secuencia |
Sequence version under test, two orthogonal identification methods, lot-level agreement between them |
EMA synthetic-peptide guideline; ICH Q6B |
|
Impurity profiling |
Peptide-related impurity list with thresholds applied, unresolved-peak treatment, validated method with forced degradation |
Guía EMA (0.1/0.5/1.0%); ICH Q2(R2) |
|
Scale-up |
Two-scale comparison of the same process, scaling factors for scale-dependent steps, perfiles ar impureza ga̲ yoho escalas |
ICH Q11 |
|
ntsa̲ liberación |
USP 〈71〉 ne 〈85〉 protocolos ko datos incubación ne inhibición yá mejora, rastros auditoría habilitados, datos crudos recuperables |
USP 〈71〉 yá 〈85〉; 21 ' 11; MHRA ALCOA |
hñu implicaciones siguen pa ya 'na'ño lectores. 'nar comprador patrocinador da japi 'nar goxthi 'be̲di komongu 'nar riesgo program, hingi 'nar brecha documentación, getho ya goxthi falla njut'i mäs nä'ä ar pa ahorró. 'nar CRO da esperar ar zohni 'nehe ne hoki ar comparación yoho ya escalas 'be̲tho ar etapa propuesta. 'nar revisor presentación da lei sección impurezas pa ya umbrales realmente aplicados, ya da expediente 'nar péptido construido dige ya 'bede Q3A xi 'be̲di ár especificación.
ár nt'ent'i ar nt'ent'i ar ho̲ntho ne ya citable: if any one of the four gates is missing from the proposal and the supplier will not commit to supplying the evidence before contract signature, the timeline is not a commitment and should not enter your filing plan.
Njäts'i nu'bu
Lonza’s three-month tox-supply and six-month IND figures are real, footnoted and specific to a biologics platform operating on pool material with a defined starting point. They do not describe a peptide program, and the peptide literature explains why: sub-100% per-coupling yield, sequence-dependent aggregation, and byproducts that HPLC alone will not reveal.
The four gates hold regardless of which supplier you are evaluating. Sequence confirmation must be orthogonal and lot-level. Impurity profiling must apply the peptide thresholds of 0.1% reporting, 0.5% identification and 1.0% calificación, with unresolved peaks treated as combinations. Scale-up must rest on a two-scale comparison with stated scaling factors. Release testing must carry the 14-day sterility incubation, the endotoxin inhibition/enhancement data, and audit trails that satisfy 21 CFR 11.10(a) and MHRA ALCOA.
The earned takeaway is that speed and readiness are different claims, and only one of them is transferable between modalities. The next step is to take the proposal in front of you and mark which of the four gates it answers with evidence you can open. Where a gate is blank, that is the question to send back before signature.
divulgación ar editor: M. O; availability and performance for a specific construct require project-specific evidence.
